[Glucagon-like peptide 1 analogues in the treatment of type 2 diabetes mellitus].
A Cochrane analysis concluded that glucagon-like peptide-1 (GLP-1) analogues were effective for the improvement of glycaemic control in patients with type 2 diabetes. What is the significance for the treatment of Danish patients with type 2 diabetes? In Denmark, two drugs exist, exenatid and liraglutid, and they both reduce HbA1c with approx. 1%. Compared with sulfonylurea and insulin, the advantage of GLP-1 analogues is not only that they rarely induce hypoglycaemia, but also that body weight is reduced. On the other hand, no long-term results exist with regard to impact on the cardiovascular system, and no complete overview of possible side effects has been presented either.
Endokrinologisk Afdeling M, Odense Universitetshospital, Kløvervænget 6, 5000 Odense C, Denmark. henning.beck-nielsen@ouh.regionsyddanmark.dk
Henning
H
Beck-Nielsen
D003718:Denmark; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D019317:Evidence-Based Medicine; D052216:Glucagon-Like Peptide 1 / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D006442:Glycated Hemoglobin / Q000378:metabolism; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D054795:Incretins / Q000627:therapeutic use*
D052216:Glucagon-Like Peptide 1; D006442:Glycated Hemoglobin; D007004:Hypoglycemic Agents; D054795:Incretins